Research programme: anti CD44v6 CAR transduced T-cells - MolMed/San Raffaele Hospital

Drug Profile

Research programme: anti CD44v6 CAR transduced T-cells - MolMed/San Raffaele Hospital

Alternative Names: CAR-CD44v6 immune gene therapy - MolMed; CARCD44v6; Chimeric antigen receptor CD44v6 immune gene therapy - MolMed

Latest Information Update: 19 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scientific Institute San Raffaele
  • Class CAR-T cell therapies; Gene therapies
  • Mechanism of Action CD44 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 13 Apr 2015 MolMed exercises its option right to acquire CAR-CD44v6 project from San Raffaele Hospital (OSR)
  • 13 Apr 2015 Preclinical trials in Haematological malignancies in Italy (Parenteral)
  • 13 Apr 2015 Preclinical trials in Solid tumours in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top